CN1270709C - Tiotropium aerosol inhalant and its preparation method - Google Patents
Tiotropium aerosol inhalant and its preparation method Download PDFInfo
- Publication number
- CN1270709C CN1270709C CN 200410015951 CN200410015951A CN1270709C CN 1270709 C CN1270709 C CN 1270709C CN 200410015951 CN200410015951 CN 200410015951 CN 200410015951 A CN200410015951 A CN 200410015951A CN 1270709 C CN1270709 C CN 1270709C
- Authority
- CN
- China
- Prior art keywords
- tiotropium bromide
- powder
- aminoacid
- inhaled
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
Abstract
The present invention relates to a tiotropium bromide inhalant powder medicament and a preparation method thereof. The mixed solution of tiotropium bromide and amino acid form super micropowder after spray drying, the super micropowder and an amount of recrystallization lactose are filled in capsules or prepared into other proper medicament types after being mixed, and the medicament is taken by the lung to enter respiratory tracts in a dry powder form by a special medicament administration device and used for treating chronic obstructive diseases. The present invention has the advantages of simple preparation technology and no organic solvent or preservative in the process of preparation, and the prepared powder medicament has the advantages of good powder flowability, exact dosage, high deposition quantity in effective positions and no stimulation on mucosa. The preparation method can be used for preparing powder medicaments, such as albuterol, Salmeterol, Budesonide, cromolyn sodium, etc.
Description
Technical field
The invention belongs to pharmaceutical field, relate to a kind of pharmaceutical preparation of sucking the powder spray deposition ratio in the effective position and preparation method thereof that improves, the medicine one tiotropium bromide pulmonary that is specifically related to treat chronic obstructive pulmonary disease sucks pharmaceutical preparation of powder spray and preparation method thereof.
Background technology
Chronic obstructive pulmonary disease (COPD) is common, as to have airflow obstruction feature chronic bronchitis or the respiratory tract disease that emphysema cause.Along with progression of disease, will have a strong impact on patient's work and life, even take place dead.According to Inpharma in 1998 report, COPD is the 5th cause of death in the world, then is the 4th cause of death in the U.S., anticipates that the year two thousand twenty will become the 3rd cause of death in the whole world.Show that according to Decision Resource (DR) company current research the COPD sickness rate of 7 countries in the world (U.S., method, moral, meaning, west, English, day) more than 45 years old in the population is about 4%-6%.The sickness rate of the present COPD of China is 3.3%-5.1%, because of the mortality rate of concurrent other diseases of COPD very high.
Tiotropium bromide is that its selectively acting is in M by the long-acting anticholinergic thing of a new generation of Boehringer Ingelheim company exploitation
1, M
3Receptor, the selectivity ratios ipratropium bromide is strong.Tiotropium bromide makes patient's COPD bronchiectasis reach 24 hours, and being only needs medication COPD curative once first kind of every day.
Clinical tiotropium bromide dosage form commonly used is a powder spray at present, uses for sucking patient pulmonary.Powder spray is a kind of inspiratory airflow by the patient, with be loaded in the suction apparatus medicine or (with) the carrier micropowder, suck respiratory tract through aerodynamic atomization, make medicine enter therapentic part or human lung and play a class preparation of therapeutical effect, have targeting, efficient, quick-acting, characteristics such as toxic and side effects is little.Known tiotropium bromide preparation technology has 1) the tiotropium bromide micropowder of supersonic speed pulverizing and the lactose of certain particle size are made powder for sucking: 2) aminoacid of tiotropium bromide micropowder that supersonic speed is pulverized and certain particle size is made powder for suction.Because the dosage of tiotropium bromide is very little, common every capsules contains tiotropium bromide 21.67 μ g, adopt above-mentioned known method can not make the comparatively ideal powder of uniformity of dosage units, and the deposition ratio in the effective position effect of the powder spray that these two kinds of methods make is often not good.
Summary of the invention
It is simple to the purpose of this invention is to provide a kind of preparation method, and dosage is accurate, can fully be enriched in the inhaled tiotropium bromide powder preparation of target organ again, is used for the treatment of chronic obstructive pulmonary disease.
In order to achieve the above object, the present invention adopts following technical scheme,
The target organ of medicine of the present invention is respiratory tract and pulmonary, can adopt powder spray and aerosol dosage forms, but because aerosol contains propellant can cause environmental pollution and should not adopt.
The present invention mixes the back spray drying with the tiotropium bromide medicine with the carrier of amino acids, after making light-weight low-density complex superfine powder, fully mix the back filled capsules or make other suitable inhaled tiotropium bromide powder preparation with an amount of recrystallization lactose again, after special-purpose doser administration, enter the respiratory tract pulmonary administration, be used for the treatment of chronic obstructive pulmonary disease with dry powder form.Prepared inhaled tiotropium bromide powder preparation has the accuracy and the higher effective position deposition of good divided dose.
Described tiotropium bromide medicine can be anhydride or monohydrate.
It is generally acknowledged that particle diameter could arrive pulmonary at the drug powder of 0.5-7 μ m.So need micronization at the technical process Chinese medicine.The micronization mode that the present invention adopts has spray drying method, fluid bed supersonic airstream comminuting method, high speed polishing, ball-milling method, solvent method etc.Because the price of tiotropium bromide crude drug is very expensive, adopt mechanical crushing method to need a large amount of crude drug, and the particle size that obtains is inhomogeneous, 2-3 μ m is the limit of mechanical crushing method in addition.Given this, the present invention adopts spray drying method for preparation tiotropium bromide-amino acid complex micropowder, and the gained grain size of micropowder is 0.5 μ m to 10 μ m, and the preferable particle size scope is 0.5-5 μ m, can satisfy the particle diameter requirement that sucks powder spray fully.
Because the amount of contained principal agent is very low in this preparation, is 0.01-1%,,, obtain the satisfactory suction powder of content and loading amount to increase volume so adopt certain carrier.It is excipient that the present invention adopts the good extremely-low density carrier amino acids of atomization, increases the volume of principal agent, is convenient to mixing and divided dose, the more important thing is that spray-dired aminoacid possesses the morphosis of hollow, and more onesize solid-core support density is low.Afterwards, add carrier recrystallization lactose again, increase the flowability of powder.
Described aminoacid comprises alanine, valine, isoleucine, glycine, phenylalanine, proline, tryptophan, serine, tyrosine, cysteine, methionine, glutamic acid, threonine, aspartic acid, glutamine, lysine, arginine, histidine and agedoite.
Experiment confirm, the size of carrier particle diameter has certain influence to its flowability and respiratory mucosa stimulation.The particle diameter of carrier is too big, though good fluidity has stimulation to respiratory mucosa, the too little then flowability of particle diameter is not good.The recrystallization lactose carrier mean diameter that the present invention selects for use is 40 μ m to 120 μ m.
The present invention uses aminoacid separately respectively than both with the lactose use in conjunction better divided dose accuracy and deposition ratio in the effective position.Aminoacid and lactose use in conjunction result show, along with the increase of aminoacid micropowder ratio, deposition ratio in the effective position is in rising trend, but amino acid whose ratio is too high, the flowability of powder is not good, so the ratio of selecting for use aminoacid to mix with the recrystallization lactose is preferably 5: 95.
Table 1 is the influence result of the mixed proportion of aminoacid and lactose to deposition ratio in the effective position and flowability.
Table 1
| Serine (g) | Lactose (g) | Serine/lactose | Deposition ratio in the effective position (%) | Remarks |
| 0 2 4 10 20 | 200 198 196 190 180 | 1/99 2/98 5/95 10/90 | 11 12 14 18 19 | Because the content of principal agent is extremely low, so divided dose is inaccurate, divided dose difference between the capsule is because the content of principal agent is extremely low, so divided dose is inaccurate, the divided dose between the capsule is poor |
Pharmaceutical preparation of the present invention is the compositions that capsule contains the tiotropium bromide and the carrier of unit dose, every capsules contains tiotropium bromide 5-50 μ g, the tiotropium bromide that preferably contains 21.67 μ g, the total amount of capsule Chinese medicine and excipient is 5-50mg, preferred 10-20mg, the dry micropowder of described medicine and carrier mixing can single dose the form hard capsule of packing into, or place the blister of powder inhaler, or place the powder inhaler of multiple dose with the form of drug-reservoir.
Powder spray of the present invention does not contain propellant, can not cause environmental pollution, and the medicine in the powder spray absorbs by the abundant down blood capillary of respiratory mucosa, thereby as the respiratory mucosa absorbable preparation, has following characteristics: 1. do not have the gastrointestinal tract Degradation; 2. there is not liver first-pass effect; 3. drug absorption is rapid, and is rapid-action after the administration; 4. the bioavailability of macromolecular drug can be by the improve that should be used for of absorption enhancer or other method; 5. small-molecule drug is particularly useful for respiratory tract and directly sucks or spray into administration: 6. directly enter the body circulation after the drug absorption, reach the purpose of whole body therapeutic; 7. can be used for the big medicine of water solublity that gastrointestinal tract is difficult to absorb; 8. good patient compliance is specially adapted to the patient that former need carry out the long term injections treatment; 9. play the medicine of local action, dosage obviously reduces, and toxic and side effects is little.Preparation technology of the present invention is simple, organic solvent-free and antiseptic in the preparation process, and the preparation powder flowbility that makes is good, and dosage is accurate, and the deposition ratio in the effective position height is non-stimulated to mucosa.Preparation method of the present invention also can be used for albuterol, salmaterol, the anti-moral in cloth ground, the preparation of powder sprays such as sodium cromoglicate.
The specific embodiment
Embodiment 1
| The supplementary material title | 10000 capsules consumptions |
| Tiotropium bromide serine lactose | 0.4334g 2.0g adds to 200.0g |
By above-mentioned formula ratio, get tiotropium bromide 0.8668g and serine 4.0g, with the solution that is made into 100ml behind the deionized water dissolving, 130 ℃ of control inlet temperature, 80 ℃ of leaving air temps, air velocity 10%, sample introduction speed 10%, carry out spray drying, obtain the spray drying micropowder, in exsiccator, preserve behind 105 ℃ of dry 2h.
Take by weighing lactose 300g, add water 250ml water-bath and make moltenly, cross No. 5 sand core funnels, the filtrate room temperature is placed 24h, and crystallization is separated out gradually, and the reduced vacuum drying obtains the recrystallization lactose.With the lactose porphyrize, cross 200 mesh sieves, in exsiccator, preserve equally.
Take by weighing 2.0g tiotropium bromide one serine spray drying micropowder, add the 198.0g lactose, repeat mistake 200 mesh sieves 3 times, behind the mensuration medicament contg, in incapsulating with the equivalent method of progressively increasing.Every hard capsule loading amount is about 20mg, and containing tiotropium bromide is 43.34 μ g.
Embodiment 2
| The supplementary material title | 10000 capsules consumptions |
| Tiotropium bromide serine lactose | 0.4334g 10.0g adds to 200.0g |
By above-mentioned formula ratio, the same method preparation, every hard capsule loading amount is about 20mg, contains tiotropium bromide and answers 43.43 μ g.
Embodiment 3
| The supplementary material title | 10000 capsules consumptions |
| Tiotropium bromide serine lactose | 0.4334g 20.0g adds to 200.0g |
By above-mentioned formula ratio, the same method preparation, every hard capsule loading amount is about 20mg, and containing tiotropium bromide is 43.43 μ g.
Compare different aminoacids and lactose mixed proportion, the result shows, along with the increase of aminoacid micropowder ratio, deposition ratio in the effective position is in rising trend, but amino acid whose ratio is too high, and the flowability of powder is not good, and 5: 95 effects of aminoacid and lactose mixed proportion are good.
Table 2 is different aminoacids and lactose mixed proportion result.
Table 2
| Serine (g) | Lactose (g) | Serine/lactose | Deposition ratio in the effective position (%) | Remarks | |
| Embodiment 1 embodiment 2 embodiment 3 | 2 10 20 | 198 190 180 | 1/99 5/95 10/90 | 12 18 19 | Because the content of principal agent is extremely low, so divided dose is inaccurate, the divided dose between the capsule is poor |
Embodiment 4
| The supplementary material title | 10000 capsules consumptions |
| Tiotropium bromide alanine lactose | 0.2167g 10.0g adds to 200.0g |
By above-mentioned formula ratio, the same method preparation, every hard capsule loading amount is about 20mg, contains tiotropium bromide and should be 21.673 μ g.
Embodiment 5
| The supplementary material title | 10000 capsules consumptions |
| Tiotropium bromide tryptophan lactose | 0.2167g 20.0g adds to 100.0g |
By above-mentioned formula ratio, the same method preparation, every hard capsule loading amount is about 10mg, contains tiotropium bromide and should be 21.673 μ g.
Embodiment 6
| The supplementary material title | 10000 capsules consumptions |
| The tiotropium bromide glycine | 0.2167g 200.0g |
By above-mentioned formula ratio, with micropowder and the 200.0g glycine that the 0.2167g supersonic airstream is pulverized, particle size range 40-120 μ m, the method that adopts equivalent to progressively increase is mixed, and every hard capsule loading amount is about 20mg, and containing tiotropium bromide is 21.67 μ g.
Embodiment 7
| The supplementary material title | 10000 capsules consumptions |
| The tiotropium bromide lactose | 0.2167g add to 200.0g |
By above-mentioned formula ratio, with micropowder and the 200.0g recrystallization lactose that the 0.2167g supersonic airstream is pulverized, particle size range 40-120 μ m, the method that adopts equivalent to progressively increase is mixed, and every hard capsule loading amount is about 20mg, and containing tiotropium bromide is 21.67 μ g.
Relatively more different flowability and the deposition ratio in the effective position that make the micropowder method, the result shows, with after medicine and the aminoacid spray drying again with the recrystallization lactose mixed powder will be behind the direct micronization of medicine than earlier again with aminoacid or lactose mixed powder better flowability and deposition ratio in the effective position be arranged, and uniformity of dosage units is better.
Table 3 is flowability and deposition ratio in the effective position results that difference makes the micropowder method.
Table 3
| Make the micropowder method | Deposition ratio in the effective position (%) | Angle of repose (°) | Emptying Rate (%) | Uniformity of dosage units (%) |
| Aminoacid-drug powder mixes simple drug powder and mixes simple micropowder with glycine and mix with the recrystallization lactose with the recrystallization lactose | 20 12 13 | 43 52 43 | 96 92 96 | 5.28 16.2 17.2 |
The present invention describes by above description and embodiment, more than is described as nonrestrictively, does not limit claim scope of the present invention.
Claims (9)
1, a kind of inhaled tiotropium bromide powder preparation is characterized in that containing medicine tiotropium bromide and aminoacid and recrystallization lactose, by following method preparation; Tiotropium bromide and the dry micronization of aminoacid mixing solution spray are formed micropowder, again with recrystallization lactose mixing filled capsules or place the blister of powder inhaler, or place the powder inhaler of multiple dose with the form of drug-reservoir, make the suction powder spray; Wherein aminoacid is excipient.
2, inhaled tiotropium bromide powder preparation according to claim 1 is characterized in that described medicine tiotropium bromide is anhydride or monohydrate.
3, inhaled tiotropium bromide powder preparation according to claim 1 is characterized in that the described aminoacid and the ratio of recrystallization lactose are 5: 95.
4, inhaled tiotropium bromide powder preparation according to claim 1 is characterized in that the particle diameter of the micropowder that described tiotropium bromide and aminoacid mixing solution form is 0.5 μ m to 10 μ m, and described recrystallization lactose particle diameter is 40 μ m to 120 μ m.
5, inhaled tiotropium bromide powder preparation according to claim 1 is characterized in that the particle diameter of the micropowder that described tiotropium bromide and aminoacid mixing solution form is 0.5-5 μ m.
6, inhaled tiotropium bromide powder preparation according to claim 1 is characterized in that every of described capsule contains tiotropium bromide 5-50 μ g, and the total amount of capsule Chinese medicine and excipient is 5-50mg.
7, inhaled tiotropium bromide powder preparation according to claim 1 is characterized in that every of described capsule contains tiotropium bromide 21.67 μ g, and the total amount of capsule Chinese medicine and excipient is 10-20mg.
8, inhaled tiotropium bromide powder preparation according to claim 1 is characterized in that described carrier aminoacid comprises alanine, valine, isoleucine, glycine, phenylalanine, proline, tryptophan, serine, tyrosine, cysteine, methionine, glutamic acid, threonine, aspartic acid, glutamine, lysine, arginine, histidine and agedoite.
9, inhaled tiotropium bromide powder preparation according to claim 1 is characterized in that described micronized mode also selects for use the fluid bed supersonic airstream to pulverize or high speed is ground or ball milling.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410015951 CN1270709C (en) | 2004-01-19 | 2004-01-19 | Tiotropium aerosol inhalant and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410015951 CN1270709C (en) | 2004-01-19 | 2004-01-19 | Tiotropium aerosol inhalant and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1557308A CN1557308A (en) | 2004-12-29 |
| CN1270709C true CN1270709C (en) | 2006-08-23 |
Family
ID=34351613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410015951 Expired - Fee Related CN1270709C (en) | 2004-01-19 | 2004-01-19 | Tiotropium aerosol inhalant and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1270709C (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100428938C (en) * | 2005-09-28 | 2008-10-29 | 天津药业研究院有限公司 | Glucocorticoid capsule type inhaling atomized powder and preparation method |
| GB0716026D0 (en) * | 2007-08-16 | 2007-09-26 | Norton Healthcare Ltd | An inhalable medicament |
| CN101422457B (en) * | 2007-10-31 | 2011-01-26 | 江苏正大天晴药业股份有限公司 | Tiotropium bromide respirable dry powder composition |
| CN102058566A (en) * | 2010-12-24 | 2011-05-18 | 中国药科大学 | Dry powder inhaler with constituent rubescensin A as well as preparation method and application thereof |
| CN103110584A (en) * | 2013-01-29 | 2013-05-22 | 青岛大学 | Tiotropium bromide powder inhalation and preparation method thereof |
| CN110302157B (en) * | 2018-03-27 | 2023-01-17 | 天津金耀集团有限公司 | Ipratropium bromide aerosol composition and preparation method thereof |
| CN110302184B (en) * | 2018-03-27 | 2023-01-17 | 天津金耀集团有限公司 | Application of lysine in quaternary ammonium salt M receptor antagonist aerosol |
| CN108451936A (en) * | 2018-06-19 | 2018-08-28 | 杭州勃锐思莫生物医药科技有限责任公司 | A kind of Tiotropium Bromide sucking preparation prepare treat lung-cancer medicament in apply |
| CN109745564A (en) * | 2019-01-28 | 2019-05-14 | 上海方予健康医药科技有限公司 | A kind of preparation method sucking dry powder composite |
| CN114272228B (en) * | 2022-01-04 | 2023-08-22 | 丽珠医药集团股份有限公司 | Tiotropium bromide inhalation microsphere, preparation method thereof and inhalation preparation |
-
2004
- 2004-01-19 CN CN 200410015951 patent/CN1270709C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1557308A (en) | 2004-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002218503B2 (en) | Powdery preparations and methods for producing the same | |
| US11116721B2 (en) | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol | |
| AU2013234080B2 (en) | Novel pharmaceutical formulations | |
| CN1270709C (en) | Tiotropium aerosol inhalant and its preparation method | |
| ES2718455T3 (en) | Inhaled sustained therapeutic formulations | |
| US20100093866A1 (en) | Pharmaceutical Formulations | |
| JP2005529874A (en) | Dry powder composition | |
| US20210322311A1 (en) | Inhalable Formulation of a Solution Containing Tiotropium Bromide and Olodaterol | |
| JP2009514779A (en) | Pharmaceutical formulation | |
| JP5697199B2 (en) | Dry powder pharmaceutical composition for inhalation | |
| WO2022116792A1 (en) | Isoniazid dry powder inhalant for treating pulmonary tuberculosis | |
| TW200404008A (en) | Composition | |
| CN107496388B (en) | Powdery preparation containing formoterol and tiotropium salt composition and preparation method thereof | |
| US20170348290A1 (en) | Novel aerosol formulations of granisetron and uses thereof | |
| US20090246281A1 (en) | Soft steroid compositions for use in dry powder inhalers | |
| JP2009513529A (en) | Pharmaceutical formulations containing magnesium stearate | |
| JP4755495B2 (en) | Combination medicine | |
| US20110123574A1 (en) | Inhalable sustained therapeutic formulations | |
| US20120034202A1 (en) | Ameliorating agent for chronic obstructive pulmonary disease | |
| CN102247335B (en) | Bufalin dry powder inhalant as well as preparation method and application thereof | |
| JP2009513531A (en) | Inhalable pharmaceutical formulations containing sugar esters | |
| CN102302475A (en) | Resibufogenin dry powder inhalant and preparation method and application thereof | |
| CN111973671B (en) | Inhalation powder inhalation of "Reduning" and preparation method thereof | |
| CN1593414A (en) | Powder inhalation of tiotropium bromide capsule type and its preparation method | |
| CN102247336B (en) | Bufothionine dry powder inhaler, and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: FUDAN UNIVERSITY ZHEJIANG SANMEN EAST ASIA PHARMAC Free format text: FORMER OWNER: ZHEJIANG SANMEN EAST ASIA PHARMACEUTICAL CO., LTD. Owner name: SHANGHAI PUKANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: FUDAN UNIVERSITY Effective date: 20100827 |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 200433 NO.220, HANDAN ROAD, SHANGHAI TO: 200135 NO.200, PEIKUN ROAD, MINHANG DISTRICT, SHANGHAI |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20100827 Address after: 200135 Shanghai city Minhang District accompany Queensland Road No. 200 Co-patentee after: Fudan University Patentee after: Shanghai Pukang Pharmaceutical Co., Ltd. Co-patentee after: Zhejiang three East Asia Pharmaceutical Co., Ltd. Address before: 220 Handan Road, Shanghai, No. 200433 Co-patentee before: Zhejiang three East Asia Pharmaceutical Co., Ltd. Patentee before: Fudan University |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060823 Termination date: 20160119 |
|
| EXPY | Termination of patent right or utility model |